药物诱导的肝损伤:使用FDA不良事件报告系统数据库 (2004-2024) 的现实世界药监测研究
Dongxuan Li1, Duan Wang2, Guili Huang1
1Department of Pharmacy, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China.
Annals of hepatology
|November 17, 2025
概括
这项研究使用FDA数据识别了经常报告的肝毒药物,突出显示抗瘤剂是药物诱导性肝损伤 (DILI) 的高风险药物类. 建议进一步关注与这些药物相关的DILI风险.
科学领域:
- 药物监督 药物监督 药物监督
- 肝病学 肝病学是一种肝病学.
- 药品安全 药品安全
背景情况:
- 药物诱导性肝损伤 (DILI) 管理依赖于及时识别罪祸首药物.
- 美国食品和药物管理局的不良事件报告系统 (FAERS) 数据库是药物监测的宝贵资源.
研究的目的:
- 使用FAERS数据调查潜在的肝毒药物.
- 确定与DILI最常相关的单一药物和药物类别.
主要方法:
- 在FAERS (2004-2024) 中对DILI相关报告的分析.
- 编制报告的罪祸首药物清单.
- 不成比例性分析以评估每个药物的DILI风险.
主要成果:
- 超过236,000份DILI报告确定了1459种罪祸首的药物.
- cetamol是报告最多的单一药物;抗瘤剂是报告最多的药物类别.
- 806种药物显示出积极的DILI信号,其中伏拉西迪尼布具有最高强度;抗瘤药物主导高风险类别.
结论:
- 从FAERS数据中生成了一个全面的DILI罪祸首药物清单.
- 抗瘤剂是DILI的一个重要问题,因为报告频率,风险信号和分布.
- 需要对与抗瘤药物相关的DILI风险提高临床警.
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
170
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
199
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
199
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
204
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
204
Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K


